5 results about "Macroglobulinemia" patented technology

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

The application discloses a sugar chain marker combination for diagnosing Waldenstrom's macroglobulinemia and application thereof, and the marker combination comprises the following N-sugar chains: cFA2_2, cFA2B, cFA2(6)G1, cFA2(3)G1, A2G2, cFA2B(3)G1, cFA2G2, cFA2BG2, A3G3_2 and aFA3G3_2. By analyzing the change of N-sugar chains on glycoprotein in blood, the application finds that specific N-sugar chain marker combination has significant correlation with WM. The marker combination has high sensitivity and high specificity in WM diagnosis, can be rapidly detected through fluorescence labeling technology, has a non-invasive advantage, can be used for early discovery and accurate diagnosis, and is helpful to improve the cure rate and survival rate of patients. In addition, the discovery of the bisecting biantennary N-sugar chain combination provides a new potential treatment target for WM, and has important clinical application value.

Disclosed herein are methods for determining whether a subject is suffering from Waldenström macroglobulinemia (WM) or a precursor condition thereof, or multiple myeloma (MM) or a precursor condition thereof. These methods comprise determining, in a sample obtained from the subject, data indicative of the proportions of two or more immune cell populations. Methods of monitoring a subject with WM, or a precursor condition thereof, are also disclosed. These methods comprise determining in tumor cells obtained from a sample obtained from the subject and a reference sample expression of two or more gene expression signatures which indicate whether the subject is at risk of disease progression.

Disclosed herein are methods for determining whether a subject is suffering from Waldenström macroglobulinemia (WM) or a precursor condition thereof, or multiple myeloma (MM) or a precursor condition thereof. These methods comprise determining, in a sample obtained from the subject, data indicative of the proportions of two or more immune cell populations. Methods of monitoring a subject with WM, or a precursor condition thereof, are also disclosed. These methods comprise determining in tumor cells obtained from a sample obtained from the subject and a reference sample expression of two or more gene expression signatures which indicate whether the subject is at risk of disease progression.